FibroGen, Inc. (FGEN) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FGEN Revenue Growth
Revenue Breakdown (FY 2024)
FGEN's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
FGEN Revenue Analysis (2013–2024)
As of May 8, 2026, FibroGen, Inc. (FGEN) generated trailing twelve-month (TTM) revenue of $-118,093,000, reflecting significant decline in growth of -97.7% year-over-year. The most recent quarter (Q3 2025) recorded $1.1 million in revenue, down 20.2% sequentially.
Looking at the longer-term picture, FGEN's 5-year compound annual growth rate (CAGR) stands at -35.1%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $256.6 million in 2019.
Revenue diversification analysis shows FGEN's business is primarily driven by Drug Product Revenue (100%). With over half of revenue concentrated in Drug Product Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including AKBA (+25.7% YoY), PTCT (-53.3% YoY), and FOLD (+20.0% YoY), FGEN has underperformed the peer group in terms of revenue growth. Compare FGEN vs AKBA →
FGEN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FGENCurrent | $-118,093,000 | -97.7% | -35.1% | -507.8% | |
 AKBA | $236M | +25.7% | -4.3% | 9.9% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 INSM | $606M | +66.7% | +29.8% | -194.0% |
FGEN Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $29.6M | -36.7% | $14.1M | 47.5% | $-150,416,000 | -507.8% |
| 2023 | $46.8M | -66.7% | $42.8M | 91.5% | $-322,721,000 | -689.5% |
| 2022 | $140.7M | -40.2% | $120.5M | 85.6% | $-301,025,000 | -213.9% |
| 2021 | $235.3M | +33.5% | $-213,883,000 | -90.9% | $-288,530,000 | -122.6% |
| 2020 | $176.3M | -31.3% | $167.4M | 95.0% | $-191,880,000 | -108.8% |
| 2019 | $256.6M | +20.5% | $255.4M | 99.6% | $-89,314,000 | -34.8% |
| 2018 | $213.0M | +69.5% | $-22,881,000 | -10.7% | $-86,693,000 | -40.7% |
| 2017 | $125.7M | -30.0% | $-70,849,000 | -56.4% | $-122,609,000 | -97.6% |
| 2016 | $179.6M | -0.7% | $-7,629,000 | -4.2% | $-53,654,000 | -29.9% |
| 2015 | $180.8M | +31.4% | $-33,261,000 | -18.4% | $-77,625,000 | -42.9% |
See FGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FGEN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FGEN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFGEN — Frequently Asked Questions
Quick answers to the most common questions about buying FGEN stock.
Is FGEN's revenue growth accelerating or slowing?
FGEN revenue declined -97.7% year-over-year, contrasting with the 5-year CAGR of -35.1%. TTM revenue fell to $-118M. This reverses the prior growth trend.
What is FGEN's long-term revenue growth rate?
FibroGen, Inc.'s 5-year revenue CAGR of -35.1% reflects the variable expansion pattern. Current YoY growth of -97.7% is below this long-term average.
How is FGEN's revenue distributed by segment?
FGEN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.